Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 75

Sort by

Sort Order Select

Journal Articles

Risk prediction for clonal cytopenia: multicenter real-world evidence

Blood (2024) 144 (19): 2033–2044.

https://doi.org/10.1182/blood.2024024756

Published: 2024

Includes: Supplemental data

Journal Articles

A Phase 1, Open-Label, Dose Escalation and Dose Expansion, Multicenter Clinical Trial to Evaluate the Safety, Pharmacokinetics, Pharmacodynamics, and Preliminary Efficacy of Lomonitinib (ZE46-0134) in Adults with FLT3 -Mutated Relapsed or Refractory Acute Myeloid Leukemia

Blood (2024) 144 (Supplement 1): 2883.4.

https://doi.org/10.1182/blood-2024-208822

Published: 2024

Journal Articles

Immunophenotypic Markers CD7 and CD56 Improve Risk Stratification of Frontline Hypomethylating Agents + Venetoclax in Newly Diagnosed AML

Curtis A Lachowiez, Daniel T Peters, Jacob Fang, Andy Kaempf, Jessica T. Leonard, Laura F. Newell, Arpita Gandhi, Gabrielle Meyers, Brandon Hayes-Lattin, Richard T. Maziarz, Rachel J. Cook, Elie Traer, Ronan T. Swords, Jeffrey W. Tyner, Joshua F Zeidner, Daniel A Pollyea, Jennifer N. Saultz

Blood (2024) 144 (Supplement 1): 4314.

https://doi.org/10.1182/blood-2024-202118

Published: 2024

Journal Articles

Azacitidine and Venetoclax with or without Donor Lymphocyte Infusion in Relapsed AML Post Allo-HSCT: A Single-Institution Retrospective Study

Daniel T Peters, Coco Chang, Anson Snow, Kaitlyn M. Buhlinger, Bianka Patel, Taylor Dennison, Stephanie Dawson, Sean Gallagher, Robyn Tolley, Angela Nichols, Daniel R. Richardson, Anastasia Ivanova, Paul Armistead, Joshua F Zeidner

Blood (2024) 144 (Supplement 1): 1481.

https://doi.org/10.1182/blood-2024-193668

Published: 2024

Journal Articles

Efficacy and Safety of Asciminib in Chronic Myeloid Leukemia in Chronic Phase (CML-CP): Interim Results from the Phase 2 ASC2ESCALATE Trial in the Cohort of Patients (Pts) after 1 Prior Tyrosine Kinase Inhibitor (TKI)

Ehab L. Atallah, Moshe Y. Levy, Paul B. Koller, Koji Sasaki, Srinivas K Tantravahi, David Andorsky, Celesteann T Bremer, Joshua F Zeidner, Marlise R. Luskin, Reinhold Munker, Daisy Yang, Dramane Laine, John Sabo, Ennan Gu, Michael J. Mauro, Jorge E. Cortes

Blood (2024) 144 (Supplement 1): 479.

https://doi.org/10.1182/blood-2024-200717

Published: 2024

Journal Articles

Clinical Outcomes and Variability Based on Baseline Cytogenetic Risk of Patients with MDS Treated with Hypomethylating Agents: An Analysis from the International Consortium for MDS (icMDS) Validate Database

Ted M. Getz, Tariq Kewan, Jan Philipp Bewersdorf, Jessica M. Stempel, Luca Lanino, Wei Wei, Najla H. Al Ali, Amy E. DeZern, Mikkael A. Sekeres, Geoffrey L. Uy, Hetty E. Carraway, Pinkal Desai, Elizabeth A. Griffiths, Eytan M. Stein, Andrew M. Brunner, Christine M. McMahon, Rory M. Shallis, Joshua F Zeidner, Michael R. Savona, Somedeb Ball, Namrata S. Chandhok, Constantine Logothetis, Aram Bidikian, Gail J. Roboz, Benjamin Rolles, Eunice S. Wang, Amyah C. Harris, Maria L Amaya, Hayley Hawkins, Justin Grenet, Zhuoer Xie, Yazan F. Madanat, Yasmin Abaza, Talha Badar, Torsten Haferlach, Jaroslaw Maciejewski, David Sallman, Anoop K Enjeti, Kamal Al-Rabi, Khalid Halahleh, Devendra Hiwase, Maria Diez-Campelo, David Valcarcel, Claudia Haferlach, Lisa Pleyer, Ioannis Kotsianidis, Vasiliki Pappa, Valeria Santini, Angela Consagra, Aref Al-Kali, Seishi Ogawa, Yasuhito Nannya, Maximilian Stahl, Matteo Giovanni Della Porta, Rami S. Komrokji, Amer M. Zeidan

Blood (2024) 144 (Supplement 1): 3219.

https://doi.org/10.1182/blood-2024-202075

Published: 2024

Journal Articles

PTPN11 Mutations Are Associated with Shorter Survival in Patients with Acute Myeloid Leukemia Treated with Hypomethylating Agents and Venetoclax

Vishvaas I Ravikumar, Jessica T. Leonard, Laura F. Newell, Arpita Gandhi, Gabrielle Meyers, Brandon Hayes-Lattin, Richard T. Maziarz, Rachel J. Cook, Elie Traer, Ronan T. Swords, Jennifer N. Saultz, Jeffrey W. Tyner, Mael Heiblig, Joshua F Zeidner, Daniel A Pollyea, Curtis A Lachowiez

Blood (2024) 144 (Supplement 1): 4312.

https://doi.org/10.1182/blood-2024-201231

Published: 2024

Journal Articles

Demographics, Characteristics, Survival and Outcomes in Older, Untreated, Acute Myeloid Leukemia Patients with NPM1 Mutations or KMT2A rearrangements from the Beat AML Master Clinical Trial

Blood (2024) 144 (Supplement 1): 1564.

https://doi.org/10.1182/blood-2024-211261

Published: 2024

Journal Articles

Influence of AML Differentiation State in Risk Stratification of Frontline Therapy with Hypomethylating Agents + Venetoclax in AML

Curtis A Lachowiez, Joshua F Zeidner, Ashley M. Eckel, Daniel T Peters, Jacob Fang, Amenech Ashango, Andy Kaempf, Fangyan Dai, Christopher A. Eide, Stephen E. Kurtz, Theodore P Braun, Ronan T. Swords, Jennifer N. Saultz, Jeffrey W. Tyner, Daniel A Pollyea

Blood (2024) 144 (Supplement 1): 62.

https://doi.org/10.1182/blood-2024-201532

Published: 2024

Journal Articles

Real-World Analysis of CPX-351 Induction in Acute Myeloid Leukemia-Myelodysplasia Related (AML-MR): An Updated Analysis from the Marrow Consortium

Daniel T Peters, Deedra Nicolet, Yazan F Madanat, Jesus D Gonzalez-Lugo, Alexander J. Ambinder, Onyee Chan, Michael Jamie Hochman, Najla H. Al Ali, Victoria Klein, Krzysztof Mrózek, Tara L. Lin, Alice Mims, Charles Foucar, Joshua F Zeidner

Blood (2024) 144 (Supplement 1): 324.

https://doi.org/10.1182/blood-2024-193667

Published: 2024

Journal Articles

Phase 2a Study of SLS009, a Highly Selective CDK9 Inhibitor, in Combination with Azacitidine and Venetoclax for Relapsed/Refractory Acute Myeloid Leukemia after Prior Venetoclax Treatment

Joshua F Zeidner, Omer Jamy, Bradley Christensen, Sharif S. Khan, Dragan Cicic, Tapan M. Kadia

Blood (2024) 144 (Supplement 1): 2877.

https://doi.org/10.1182/blood-2024-198686

Published: 2024

Journal Articles

Trial in Progress: A Randomized, Double-Blind, Placebo-Controlled, Multicenter Phase 2 Study of AK117/Placebo in Combination with Azacitidine in Patients with Newly Diagnosed Higher-Risk Myelodysplastic Syndromes (AK117-205)

Amer M. Zeidan, Hongyan Tong, Zhijian Xiao, Praneeth Baratam, Ramzi Abboud, Christopher B. Benton, Joshua F Zeidner, Uma Borate, Wanxing Chai-Ho, Yonglin Lu, Jie Yang, Mingxiu Hu, Baiyong Li, Michelle Xia, David Sallman

Blood (2024) 144 (Supplement 1): 6705.

https://doi.org/10.1182/blood-2024-200541

Published: 2024

Journal Articles

A Randomized Phase 2 Trial of 28-Day (Arm A) Versus 14-Day (Arm B) Schedule of Venetoclax + Azacitidine in Newly Diagnosed Acute Myeloid Leukemia Patients ≥ 60 Years

Blood (2024) 144 (Supplement 1): 2907.2.

https://doi.org/10.1182/blood-2024-210967

Published: 2024

Journal Articles

Impact of Response to Hypomethylating Agent-Based Therapy on Survival Outcomes in the Context of Baseline Clinical-Molecular Risk and Transplant Status in Patients with Myelodysplastic Syndromes/Neoplasms (MDS): An Analysis from the International Consortium for MDS (icMDS) Validate Database

Benjamin Rolles, Jan Philipp Bewersdorf, Tariq Kewan, Ondrej Blaha, Jessica M. Stempel, Luca Lanino, Najla H. Al Ali, Amy E. DeZern, Mikkael A. Sekeres, Geoffrey L. Uy, Hetty E. Carraway, Pinkal Desai, Elizabeth A. Griffiths, Eytan M. Stein, Andrew M. Brunner, Christine M. McMahon, Rory M. Shallis, Joshua F Zeidner, Michael R. Savona, Stacey M. Frumm, Shougat Barua, Namrata S. Chandhok, Constantine Logothetis, Aram Bidikian, Ted M. Getz, Gail J. Roboz, Eunice S. Wang, Amyah C. Harris, Maria L Amaya, Hayley Hawkins, Somedeb Ball, Justin Grenet, Zhuoer Xie, Yazan F Madanat, Yasmin Abaza, Talha Badar, Torsten Haferlach, Jaroslaw Maciejewski, David Sallman, Anoop K Enjeti, Kamal Al-Rabi, Khalid Halahleh, Devendra Hiwase, Maria Diez-Campelo, David Valcarcel, Claudia Haferlach, Lisa Pleyer, Ioannis Kotsianidis, Vassiliki Pappa, Valeria Santini, Angela Consagra, Aref Al-Kali, Seishi Ogawa, Yasuhito Nannya, Matteo Giovanni Della Porta, Rami S. Komrokji, Amer M. Zeidan, Maximilian Stahl

Blood (2024) 144 (Supplement 1): 664.

https://doi.org/10.1182/blood-2024-208034

Published: 2024

Journal Articles

Phase 1 Results: First-in-Human Phase 1/2 Study of the Menin-MLL Inhibitor Enzomenib (DSP-5336) in Patients with Relapsed or Refractory Acute Leukemia

Blood (2024) 144 (Supplement 1): 213.

https://doi.org/10.1182/blood-2024-194827

Published: 2024

Journal Articles

IDH2 Mutation Is Associated with Favorable Outcome Among Older Adults with Newly Diagnosed Acute Myeloid Leukemia Treated with Lower-Intensity Therapy

Blood (2024) 144 (Supplement 1): 4325.

https://doi.org/10.1182/blood-2024-202596

Published: 2024

Journal Articles

Outcomes and Survival in Newly Diagnosed, Older, Acute Myeloid Leukemia Patients from the Beat AML Master Trial in the Venetoclax/Azacitidine Age

Blood (2024) 144 (Supplement 1): 4324.

https://doi.org/10.1182/blood-2024-211178

Published: 2024

Journal Articles

Refined ELN 2024 risk stratification improves survival prognostication following venetoclax-based therapy in AML

Curtis A. Lachowiez, Vishvaas I Ravikumar, Jad Othman, Jenny O'Nions, Daniel T Peters, Christine McMahon, Ronan Swords, Rachel Cook, Jennifer N. Saultz, Jeffrey W. Tyner, Richard James Dillon, Joshua F. Zeidner, Daniel A. Pollyea

Blood blood.2024026925.

https://doi.org/10.1182/blood.2024026925

Published: 2024

Includes: Supplemental data

Journal Articles

Validation of the Molecular International Prognostic Scoring System (IPSS-M) in Patients (Pts) with Myelodysplastic Syndromes/Neoplasms (MDS) Who Underwent Allogenic Stem Cell Transplantation (HSCT)

Blood (2023) 142 (Supplement 1): 4980.

https://doi.org/10.1182/blood-2023-186578

Published: 2023

Journal Articles

Impact of Type of Hypomethylating Agent (HMA) Used on Outcomes of Patients (Pts) with Higher-Risk Myelodysplastic Syndromes/Neoplasms (HR-MDS) - a Large, Multicenter, Retrospective Analysis

Blood (2023) 142 (Supplement 1): 4613.

https://doi.org/10.1182/blood-2023-178728

Published: 2023

NARROW

Risk prediction for clonal cytopenia: multicenter real-world evidence

A Phase 1, Open-Label, Dose Escalation and Dose Expansion, Multicenter Clinical Trial to Evaluate the Safety, Pharmacokinetics, Pharmacodynamics, and Preliminary Efficacy of Lomonitinib (ZE46-0134) in Adults with FLT3 -Mutated Relapsed or Refractory Acute Myeloid Leukemia

Immunophenotypic Markers CD7 and CD56 Improve Risk Stratification of Frontline Hypomethylating Agents + Venetoclax in Newly Diagnosed AML

Azacitidine and Venetoclax with or without Donor Lymphocyte Infusion in Relapsed AML Post Allo-HSCT: A Single-Institution Retrospective Study

Efficacy and Safety of Asciminib in Chronic Myeloid Leukemia in Chronic Phase (CML-CP): Interim Results from the Phase 2 ASC2ESCALATE Trial in the Cohort of Patients (Pts) after 1 Prior Tyrosine Kinase Inhibitor (TKI)

Clinical Outcomes and Variability Based on Baseline Cytogenetic Risk of Patients with MDS Treated with Hypomethylating Agents: An Analysis from the International Consortium for MDS (icMDS) Validate Database

PTPN11 Mutations Are Associated with Shorter Survival in Patients with Acute Myeloid Leukemia Treated with Hypomethylating Agents and Venetoclax

Demographics, Characteristics, Survival and Outcomes in Older, Untreated, Acute Myeloid Leukemia Patients with NPM1 Mutations or KMT2A rearrangements from the Beat AML Master Clinical Trial

Influence of AML Differentiation State in Risk Stratification of Frontline Therapy with Hypomethylating Agents + Venetoclax in AML

Real-World Analysis of CPX-351 Induction in Acute Myeloid Leukemia-Myelodysplasia Related (AML-MR): An Updated Analysis from the Marrow Consortium

Phase 2a Study of SLS009, a Highly Selective CDK9 Inhibitor, in Combination with Azacitidine and Venetoclax for Relapsed/Refractory Acute Myeloid Leukemia after Prior Venetoclax Treatment

Trial in Progress: A Randomized, Double-Blind, Placebo-Controlled, Multicenter Phase 2 Study of AK117/Placebo in Combination with Azacitidine in Patients with Newly Diagnosed Higher-Risk Myelodysplastic Syndromes (AK117-205)

A Randomized Phase 2 Trial of 28-Day (Arm A) Versus 14-Day (Arm B) Schedule of Venetoclax + Azacitidine in Newly Diagnosed Acute Myeloid Leukemia Patients ≥ 60 Years

Impact of Response to Hypomethylating Agent-Based Therapy on Survival Outcomes in the Context of Baseline Clinical-Molecular Risk and Transplant Status in Patients with Myelodysplastic Syndromes/Neoplasms (MDS): An Analysis from the International Consortium for MDS (icMDS) Validate Database

Phase 1 Results: First-in-Human Phase 1/2 Study of the Menin-MLL Inhibitor Enzomenib (DSP-5336) in Patients with Relapsed or Refractory Acute Leukemia

IDH2 Mutation Is Associated with Favorable Outcome Among Older Adults with Newly Diagnosed Acute Myeloid Leukemia Treated with Lower-Intensity Therapy

Outcomes and Survival in Newly Diagnosed, Older, Acute Myeloid Leukemia Patients from the Beat AML Master Trial in the Venetoclax/Azacitidine Age

Refined ELN 2024 risk stratification improves survival prognostication following venetoclax-based therapy in AML

Validation of the Molecular International Prognostic Scoring System (IPSS-M) in Patients (Pts) with Myelodysplastic Syndromes/Neoplasms (MDS) Who Underwent Allogenic Stem Cell Transplantation (HSCT)

Impact of Type of Hypomethylating Agent (HMA) Used on Outcomes of Patients (Pts) with Higher-Risk Myelodysplastic Syndromes/Neoplasms (HR-MDS) - a Large, Multicenter, Retrospective Analysis

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only